Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/31203527 below:

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer

Practice Guideline

Affiliations

• ¹ Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan. yhashi@med.teikyo-u.ac.jp.
• ² Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
• ³ Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
• ⁴ Department of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan.
• ⁵ Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
• ⁶ Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
• ⁷ Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
• ⁸ Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
• ⁹ Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
• ¹⁰ Department of Chemotherapy and Oncosurgery, Tokyo Medical and Dental University Medical Hospital, Tokyo, Japan.
• ¹¹ Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
• ¹² Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
• ¹³ Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
• ¹⁴ Department of Radiation Oncology, faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
• ¹⁵ Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
• ¹⁶ Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan.
• ¹⁷ Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
• ¹⁸ Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
• ¹⁹ Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Aichi, Japan.
• ²⁰ Department of Surgery, National Defense Medical College, Saitama, Japan.
• ²¹ Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
• ²² Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
• ²³ Department of Hepato-Biliary-Pancreatic and Gastrointestinal Surgery, School of Medicine, International University of Health and Welfare, Narita, Japan.
• ²⁴ Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
• ²⁵ Center for Data Science, Yokohama City University, Yokohama, Japan.
• ²⁶ Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.
• ²⁷ Division of Clinical Oncology, Kochi Health Sciences Center, Kochi, Japan.
• ²⁸ Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan.
• ²⁹ Department of Specialized Surgeries, Tokyo Medical and Dental University, Tokyo, Japan.
• ³⁰ Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, Japan.
• ³¹ Library of SEIREI, SAKURA Citizen Hospital, Sakura, Japan.
• ³² Department of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kanagawa, Japan.
• ³³ Department of Surgery, Sano City Hospital, Tochigi, Japan.
• ³⁴ Tokyo Medical and Dental University, Tokyo, Japan.

• PMID: 31203527
• PMCID: PMC6946738
• DOI: 10.1007/s10147-019-01485-z

Item in Clipboard

Practice Guideline

Yojiro Hashiguchi et al. Int J Clin Oncol. 2020 Jan.

• ¹ Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan. yhashi@med.teikyo-u.ac.jp.
• ² Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
• ³ Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
• ⁴ Department of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan.
• ⁵ Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
• ⁶ Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
• ⁷ Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
• ⁸ Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
• ⁹ Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
• ¹⁰ Department of Chemotherapy and Oncosurgery, Tokyo Medical and Dental University Medical Hospital, Tokyo, Japan.
• ¹¹ Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
• ¹² Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
• ¹³ Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
• ¹⁴ Department of Radiation Oncology, faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
• ¹⁵ Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
• ¹⁶ Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan.
• ¹⁷ Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
• ¹⁸ Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
• ¹⁹ Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Aichi, Japan.
• ²⁰ Department of Surgery, National Defense Medical College, Saitama, Japan.
• ²¹ Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
• ²² Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
• ²³ Department of Hepato-Biliary-Pancreatic and Gastrointestinal Surgery, School of Medicine, International University of Health and Welfare, Narita, Japan.
• ²⁴ Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
• ²⁵ Center for Data Science, Yokohama City University, Yokohama, Japan.
• ²⁶ Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.
• ²⁷ Division of Clinical Oncology, Kochi Health Sciences Center, Kochi, Japan.
• ²⁸ Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan.
• ²⁹ Department of Specialized Surgeries, Tokyo Medical and Dental University, Tokyo, Japan.
• ³⁰ Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, Japan.
• ³¹ Library of SEIREI, SAKURA Citizen Hospital, Sakura, Japan.
• ³² Department of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kanagawa, Japan.
• ³³ Department of Surgery, Sano City Hospital, Tochigi, Japan.
• ³⁴ Tokyo Medical and Dental University, Tokyo, Japan.

• PMID: 31203527
• PMCID: PMC6946738
• DOI: 10.1007/s10147-019-01485-z

Item in Clipboard

The number of deaths from colorectal cancer in Japan continues to increase. Colorectal cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of treatments was performed, with corrections and additions made based on knowledge acquired since the 2016 version (drug therapy) and the 2014 version (other treatments). The Japanese Society for Cancer of the Colon and Rectum guidelines 2019 for the treatment of colorectal cancer (JSCCR guidelines 2019) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment and to deepen mutual understanding between healthcare professionals and patients by making these guidelines available to the general public. These guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. Controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSCCR guidelines 2019.

Keywords: Chemotherapy; Colorectal cancer; Endoscopy; Guideline; Radiotherapy; Surgery.

PubMed Disclaimer

(1) The following corporations were disclosed by self-declaration of the Guideline Committee members and Guideline Evaluation Committee members. (2) A2 Healthcare Corp., Akita Sumitomo Co., Ltd., Array Biopharma Inc., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Covidien Japan, Inc., DAIICHI SANKYO COMPANY, Ltd., EA Pharma Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., Intuitive Surgical, Inc., Japan Clinical Research Operations, Johnson & Johnson K.K., Kaigen Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Mediscience Planning Inc., Merck Serono Co., Ltd., Merck Biopharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MRP Co., Ltd., MSD K.K., NanoCarrier Co., Ltd., Nippon Boehringer lngelheim Co., Ltd., Olympus Corporation, Ono pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Shimadzu Corporation, Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Sysmex Corporation, Taiho pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., TERUMO CORPORATION, Yakult Honsha Co., Ltd. ((2) Measures for the conflicts of interest:The Guideline Committee and the Guideline Evaluation Committee have been organized in members with a diverse range of disciplines, including surgery, internal medicine, radiology, pathology, etc., in order to minimize biased opinion. Each recommendation was made determined not on an individual opinion basis but based on voting by the whole committee members, with consensus prioritized. When voting for CQ, conflicts in relation to economic and academic interests were confirmed for each CQ, and members with conflicts of interest in the CQ abstained from voting.

Treatment strategies for cTis and…

Treatment strategies for cTis and cT1 colorectal cancer

Treatment strategies for cTis and cT1 colorectal cancer

Surgical treatment strategies for cStage…

Surgical treatment strategies for cStage 0 to cStage III colorectal cancer

Surgical treatment strategies for cStage 0 to cStage III colorectal cancer

Treatment strategies for Stage IV…

Treatment strategies for Stage IV colorectal cancer

Treatment strategies for Stage IV colorectal cancer

Treatment strategies for recurrent colorectal…

Treatment strategies for recurrent colorectal cancer

Treatment strategies for recurrent colorectal cancer

Treatment strategies for hematogenous metastases

Treatment strategies for hematogenous metastases

Treatment strategies for hematogenous metastases

Steps in the decision-making process…

Steps in the decision-making process for the first-line treatment in unresectable colorectal cancer

Steps in the decision-making process for the first-line treatment in unresectable colorectal cancer

Systemic therapy algorithm for unresectable…

Systemic therapy algorithm for unresectable colorectal cancer

Systemic therapy algorithm for unresectable colorectal cancer

An example of a surveillance…

An example of a surveillance schedule after curative resection of pStage I to…

An example of a surveillance schedule after curative resection of pStage I to pStage III colorectal cancer

Cumulative incidence of recurrence according…

Cumulative incidence of recurrence according to stage (JSCCR colorectal cancer registry: patients in…

Cumulative incidence of recurrence according to stage (JSCCR colorectal cancer registry: patients in the year 2007)

Cumulative incidence of recurrence according…

Cumulative incidence of recurrence according to the site of recurrence (JSCCR colorectal cancer…

Cumulative incidence of recurrence according to the site of recurrence (JSCCR colorectal cancer registry: patients in the year 2007)

Treatment strategies for pT1 cancer…

Treatment strategies for pT1 cancer after endoscopic resection

Treatment strategies for pT1 cancer after endoscopic resection

• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

  Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Watanabe T, et al. Int J Clin Oncol. 2012 Feb;17(1):1-29. doi: 10.1007/s10147-011-0315-2. Epub 2011 Oct 15. Int J Clin Oncol. 2012. PMID: 22002491

• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.

  Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Watanabe T, et al. Int J Clin Oncol. 2018 Feb;23(1):1-34. doi: 10.1007/s10147-017-1101-6. Epub 2017 Mar 27. Int J Clin Oncol. 2018. PMID: 28349281 Free PMC article.

• Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.

  Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Watanabe T, et al. Int J Clin Oncol. 2015 Apr;20(2):207-39. doi: 10.1007/s10147-015-0801-z. Epub 2015 Mar 18. Int J Clin Oncol. 2015. PMID: 25782566 Free PMC article.

• Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version).

  Ishida H, Yamaguchi T, Tanakaya K, Akagi K, Inoue Y, Kumamoto K, Shimodaira H, Sekine S, Tanaka T, Chino A, Tomita N, Nakajima T, Hasegawa H, Hinoi T, Hirasawa A, Miyakura Y, Murakami Y, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Sugihara K, Watanabe T; Japanese Society for Cancer of the Colon and Rectum. Ishida H, et al. J Anus Rectum Colon. 2018 May 25;2(Suppl I):S1-S51. doi: 10.23922/jarc.2017-028. eCollection 2018. J Anus Rectum Colon. 2018. PMID: 31773066 Free PMC article. Review.

• Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis.

  Okusaka T, Nakamura M, Yoshida M, Kitano M, Uesaka K, Ito Y, Furuse J, Hanada K, Okazaki K; Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. Okusaka T, et al. Pancreas. 2020 Mar;49(3):326-335. doi: 10.1097/MPA.0000000000001513. Pancreas. 2020. PMID: 32132516 Free PMC article. Review.

• Multicenter prospective study on anastomotic leakage after right-sided colon cancer surgery with laparoscopic intracorporeal overlap anastomosis (KYCC 2101).

  Kazama K, Numata M, Mushiake H, Sugano N, Godai T, Higuchi A, Ishiguro T, Atsumi Y, Shinoda S, Saito A. Kazama K, et al. Ann Gastroenterol Surg. 2024 Jun 5;8(5):836-844. doi: 10.1002/ags3.12831. eCollection 2024 Sep. Ann Gastroenterol Surg. 2024. PMID: 39229568 Free PMC article.

• Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.

  Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, Dazai M, Tateyama M, Sasaki Y, Miyagishima T, Tsuji Y, Katagiri M, Nakamura M, Sogabe S, Hatanaka K, Meguro T, Kobayashi T, Ishiguro A, Muto O, Shindo Y, Kotaka M, Ando T, Takagi R, Sakamoto N, Sakata Y. Nakatsumi H, et al. Front Oncol. 2022 Nov 9;12:939425. doi: 10.3389/fonc.2022.939425. eCollection 2022. Front Oncol. 2022. PMID: 36439491 Free PMC article.

• Meckel's diverticulum adenocarcinoma accompanied with vitelline duct remnant and huge cystic lesion: A rare case report.

  Tawada M, Misao Y, Ichikawa K, Tanaka H. Tawada M, et al. Int J Surg Case Rep. 2020;75:16-22. doi: 10.1016/j.ijscr.2020.08.061. Epub 2020 Sep 2. Int J Surg Case Rep. 2020. PMID: 32916613 Free PMC article.

• Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment.

  Ge P, Wan N, Han X, Wang X, Zhang J, Long X, Wang X, Bian Y. Ge P, et al. Front Pharmacol. 2022 Aug 30;13:914683. doi: 10.3389/fphar.2022.914683. eCollection 2022. Front Pharmacol. 2022. PMID: 36110513 Free PMC article.

• Japanese multicenter prospective study investigating laparoscopic surgery for locally advanced rectal cancer with evaluation of CRM and TME quality (PRODUCT trial).

  Takemasa I, Hamabe A, Ito M, Matoba S, Watanabe J, Hasegawa S, Kotake M, Inomata M, Ueda K, Uehara K, Sakamoto K, Ikeda M, Hanai T, Konishi T, Yamaguchi S, Nakano D, Yamagishi S, Okita K, Ochiai A, Sakai Y, Watanabe M; Japan Society of Laparoscopic Colorectal Surgery. Takemasa I, et al. Ann Gastroenterol Surg. 2022 Jul 3;6(6):767-777. doi: 10.1002/ags3.12592. eCollection 2022 Nov. Ann Gastroenterol Surg. 2022. PMID: 36338586 Free PMC article.

1. 1. Japanese Society for Cancer of the Colon and Rectum . JSCCR guidelines 2016 for the treatment of colorectal cancer. Tokyo: Kanehara & Co., Ltd.; 2016. - PMC - PubMed
2. 1. Japanese Society for Cancer of the Colon and Rectum . Japanese classification of colorectal, appendiceal, and anal carcinoma, third. English. Tokyo: Kanehara & CO., Ltd.; 2019. - PMC - PubMed
3. 1. Fukui T, Yamaguchi N, Morizane T. Minds handbook for clinical practice guideline development 2014. Tokyo: Igaku Shoin; 2014.
4. 1. Aihara M, Mihara H, Murayama T. GRADE system for clinical practice guideline-therapeutic intervention. Hirosaki: Toppan Media; 2010.
5. 1. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4:38. - PMC - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3